FAQ/Help |
Calendar |
Search |
Today's Posts |
06-06-2017, 02:18 PM | #1 | ||
|
|||
Junior Member
|
I have been following this company from NZ for a year or so now. Seems they might be onto something.
"6 June 2017 – Sydney, Australia & Auckland, New Zealand – 130 weeks after treatment a ll four patients who took part in Living Cell Technologies Limited’s Phase I/IIa clinical study of NTCELL ® for Parkinson’s disease remain well and there are no safety concerns. The primary clinical endpoint of this initial open clinical study , involving the implantation of 40 NTCELL capsules into the putamen on one side of the brain only, is safety. " |
||
Reply With Quote |
06-06-2017, 08:11 PM | #2 | ||
|
|||
Member
|
Here is a link to the full press release (PDF), which contains a bit more information:
http://www.lctglobal.com/upload/news...30%20weeks.pdf |
||
Reply With Quote |
"Thanks for this!" says: | GerryW (06-07-2017) |
Reply |
|
|
Similar Threads | ||||
Thread | Forum | |||
Ear stopping up?? | Myasthenia Gravis | |||
New here just stopping in to say hi. | New Member Introductions | |||
Stopping in to say Hi! | Multiple Sclerosis | |||
Stopping In To Say Hi! | The Stumble Inn | |||
Just stopping by... | Survivors of Suicide |